Screener
Denali Therapeutics Inc. DNLI Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s cash & equivalents?
- Denali Therapeutics Inc. (DNLI) reported cash & equivalents of $204.64M in Q2 2026.
- How has Denali Therapeutics Inc.'s cash & equivalents changed year-over-year?
- Denali Therapeutics Inc.'s cash & equivalents increased by 41.8% year-over-year, from $144.31M to $204.64M.
- What is the long-term trend for Denali Therapeutics Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Denali Therapeutics Inc.'s cash & equivalents has grown at a -16.3% compound annual growth rate (CAGR), from $508.64M to $208.43M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Denali Therapeutics Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude